Update
$Clene (CLNN.US)$ Clene Inc. unveiled the preliminary design for RESTORE-ALS, a significant Phase 3 clinical trial of their CNM-Au8 30 mg treatment, at the 2024 NEALS Meeting. This development marks a pivotal moment in their research efforts, aiming to bring new treatment options for ALS patients. Investors and market enthusiasts may find this an exciting opportunity as the company progresses in its groundbreaking trial.
免责声明：社区由Moomoo Technologies Inc.提供，仅用于教育目的。
更多信息
评论
登录发表评论
